铂耐药卵巢癌的免疫治疗进展

Immunotherapy for platinum resistant ovarian cance:A literature review

卵巢癌的病死率居妇科肿瘤之首,尽管大多数患者在接受首次治疗后可完全缓解(complete response,CR),然而仍有大约一半以上的患者在五年内复发,最终出现铂类药物化疗耐药,预后差,到目前为止铂耐药的患者仍没有有效的治疗方案。越来越多的研究表明免疫治疗可以改善多种实体瘤患者的预后。本文回顾了目前有关免疫治疗在铂耐药卵巢癌的最新研究,以期为铂耐药卵巢癌临床治疗提供新的思路和依据。

Ovarian cancer has the highest mortality rate among gynecological tumors.Although complete response(CR)can be achieved in most patients after initial treatment,its prognosis is often poor because of its critical prognostic factor,platinum-free interval(PFI)and its relapse within five years still happens in more than half of the affected patients.So far there is no effective treatment for the patients.The main treatment regimen for patients with platinum-resistant ovarian cancer is currently single-drug chemotherapy,which is comprehensively practiced clinically as a standard therapy.Meanwhile,an increasing number of studies show that immunotherapy can improve the prognosis of patients with a variety of solid tumors.Here,we reviewed the current evidence for the use of immunotherapy in the treatment of platinum-resistant ovarian cancer so as to provide new clues and basis for its clinical treatment.